Does ERIBULIN Cause Malignant neoplasm progression? 594 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 594 reports of Malignant neoplasm progression have been filed in association with ERIBULIN (eribulin mesylate). This represents 11.8% of all adverse event reports for ERIBULIN.
594
Reports of Malignant neoplasm progression with ERIBULIN
11.8%
of all ERIBULIN reports
228
Deaths
158
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ERIBULIN?
Of the 594 reports, 228 (38.4%) resulted in death, 158 (26.6%) required hospitalization, and 24 (4.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ERIBULIN. However, 594 reports have been filed with the FAERS database.
What Other Side Effects Does ERIBULIN Cause?
Neutropenia (675)
Myelosuppression (520)
Febrile neutropenia (448)
Neutrophil count decreased (294)
Neuropathy peripheral (290)
White blood cell count decreased (289)
Pyrexia (275)
Disease progression (211)
Fatigue (209)
Anaemia (188)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ERIBULIN Alternatives Have Lower Malignant neoplasm progression Risk?
ERIBULIN vs ERLOTINIB
ERIBULIN vs ERTAPENEM
ERIBULIN vs ERTUGLIFLOZIN PIDOLATE
ERIBULIN vs ERYTHROMYCIN
ERIBULIN vs ERYTHROMYCIN ETHYLSUCCINATE